CTXR — Citius Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1506251 ·
Last close
$0.54
Market Cap
$14.82M
52W High
$1.03
52W Low
$0.48
ADV30
630,073
Next earnings
2026-08-14
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 1,667,298 | 1,338,420 | -32,194,786 | -21,231,140 | 132,540,579 | 4,590,174 | 63,456,026 |
| Dec 2025 | 3,944,111 | 3,154,903 | -9,019,208 | -8,220,785 | 140,391,730 | 7,721,393 | 46,923,760 |
| Sep 2025 | 0 | — | -8,437,309 | -7,959,288 | 130,938,025 | 4,252,290 | 53,410,425 |
| Jun 2025 | 0 | — | -8,788,007 | -8,789,872 | 127,676,859 | 6,089,126 | 60,115,929 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-31,596,253
Investing CF
$-5,000,000
Financing CF
$46,910,017
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.40
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-268,256,054
Inventory
$22,659,590
Receivables
$1,079,055
ST Investments
—
EBIT TTM
$-54,433,292
Pretax Income TTM
$-54,889,643
Interest Exp TTM
$456,351
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$5,611,409
EBITDA
$-53,851,096
Free Cash Flow
$-33,459,172
Enterprise Value
$18,632,062
Total Cash
$4,590,174
Total Debt
$808,162
Shares Out
27,452,570
Trailing EPS
$-2.14
Book Value
$2.75
ROE
-83.6%
ROA
-27.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Sep 2025 | 0 | -38,525,608 | -37,433,911 | 130,938,025 | 53,410,425 | — | -26,552,738 |
| Sep 2024 | 0 | -41,995,681 | -39,138,839 | 116,651,751 | 42,549,921 | — | -28,201,375 |
| Sep 2023 | 0 | -36,732,018 | -32,542,912 | 103,611,150 | 12,179,662 | — | -29,060,212 |
| Sep 2022 | 0 | -33,316,045 | -33,640,646 | 113,999,302 | 10,573,057 | — | -28,361,256 |
| Sep 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.81
Max Pain — expiry 2026-08-21 (volume-derived — Yahoo OI feed degraded)
max pain strike: $1.00 · spot: $0.54 · call volume: 2 · put volume: 21
Expected Move to 2026-08-21:
±$0.26
(48.15%) —
implied range
$0.28 –
$0.80
· ATM straddle on $0.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MBRX | Moleculin Biotech, Inc. | $14.94M | $2.80 | — |
| INTI | Inhibitor Therapeutics, Inc. | $14.67M | $0.09 | — |
| LEXX | Lexaria Bioscience Corp. | $15.13M | $0.61 | — |
| HIND | Vyome Holdings, Inc | $15.30M | $2.18 | — |
| SCNX | Scienture Holdings, Inc. | $15.76M | $0.39 | — |
News headlines (Yahoo Finance, 1h cache)
Citius Oncology Highlights Phase 1 Data in an Investigator-Initiated Study of LYMPHIR® (denileukin diftitox-cxdl) in Combination with Pembrolizumab in Recurrent or Refractory Gynecologic Malignancies
2026-06-01 11:00 · Yahoo
Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting
2026-05-26 12:00 · Yahoo
Is Citius Pharmaceuticals, Inc. (CTXR) among the Best Rated Penny Stocks to Buy According to Wall Street Analysts?
2026-05-24 11:49 · Yahoo
Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
2026-05-15 20:30 · Yahoo
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
2026-05-15 20:30 · Yahoo
Citius Oncology Ships First International Order of LYMPHIR™ to Europe
2026-04-29 12:00 · Yahoo
Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules
2026-04-24 20:30 · Yahoo
Citius Pharmaceuticals Secures $5M Through Equity Offering
2026-04-24 14:48 · Yahoo
Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules
2026-04-24 12:00 · Yahoo
We Might See A Profit From Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Soon
2026-04-21 17:09 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.